DV
Dividend Vision

GRCE — Grace Therapeutics, Inc.

Grace Therapeutics, Inc. (GRCE)

Total return is -99.6% over the past 14.5 years, 741.0 points behind SPY at 641.4%. Its deepest 1-year drawdown was 59.6%.

Grace Therapeutics, Inc. is a biopharmaceutical company developing injectable, oral, and topical pharmaceutical products for rare and orphan diseases, with lead candidates targeting aneurysmal subarachnoid hemorrhage, Ataxia-Telangiectasia, and postherpetic neuralgia pain. The company does not currently distribute dividends. Grace Therapeutics appeals primarily to investors seeking exposure to early-stage drug development rather than income-focused investors.

GRCE key facts

Asset type
Stock
Asset class
Equity
Inception date
02/07/2012
Last close
$2.16
Market cap
$40,196,844
Average volume
397800.0
Beta
0.371
Payout ratio
0.0
Forward P/E
2.1697
EPS
$-0.47